Marzia Del Re - Concepedia

Author

Marzia Del Re

Also Known As

Jeffrey A Engelman, M Del Re, M. Del Re, M. Del Re, Marzia DEL RE, Marzia Del Re, Marzia Re, Marzia del Re, Re, Marzia Del, Romano Danesi

268

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

University of Pisa Azienda Ospedaliera Universitaria Pisana Fondazione IRCCS Istituto Nazionale dei Tumori Istituti di Ricovero e Cura a Carattere Scientifico University of Parma

About

Marzia Del Re is an author at University of Pisa specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	692
2	Health Sciences	2	2	27
3	Engineering	1	1	279
4	Nursing	1	1	19
5	Public Health	1	1	48

Marzia Del Re

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan Chiara Cremolini, Daniele Rossini, Emanuela Dell’Aquila, JAMA Oncology	2018	397
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients Marzia Del Re, Elisa Biasco, Stefania Crucitta, European Urology UrologyEngineeringCancer GenomicsHormonal TherapyProstatic Disease	2016	279
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC Marzia Del Re, Riccardo Marconcini, G. Pasquini, British Journal of Cancer	2018	242
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy Roberta Minari, Paola Bordi, Marzia Del Re, Lung Cancer MedicineSclc TransformationT790m DeterminationPharmacologyPathology	2017	106
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients Marzia Del Re, Ilaria Bertolini, Stefania Crucitta, Breast Cancer Research and Treatment Tumor BiologyBreast OncologyOncologyClinical ResistanceMedicine	2019	97
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer Marzia Del Re, Caterina Vivaldi, Eleonora Rofi, Scientific Reports	2017	88
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) Mohamed A. Gouda, Filip Jankú, Adam Wahida, Annals of Oncology	2023	87
Contribution of <i>KRAS</i> mutations and c.2369C > T (p.T790M) <i>EGFR</i> to acquired resistance to EGFR-TKIs in <i>EGFR</i> mutant NSCLC: a study on circulating tumor DNA Marzia Del Re, Marcello Tiseo, Paola Bordi, Oncotarget	2016	84
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance Annamaria Mascolo, Cristina Scavone, Carmen Ferrajolo, Drug Safety	2021	78
Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA Manouk K. Bos, Kazem Nasserinejad, Maurice P.H.M. Jansen, Molecular Oncology GeneticsDna AnalysisPathologyTumor-specific VariantsNucleic Acid Biomarkers	2020	55

Page 1